Integra LifeSciences Holdings Corp. - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated April 30, 2026, reports significant executive leadership changes at Integra LifeSciences Holdings Corporation. The filing details the appointment of a new President and Chief Executive Officer (CEO) and a new Chief Commercial Officer (CCO), effective May 1, 2026, alongside the departure of the former CEO.
Key Financial Metrics
This filing is a current report regarding corporate governance and executive compensation; it does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
- CEO Transition: Dr. Stuart M. Essig was appointed President and CEO, effective May 1, 2026. He succeeds Mojdeh Poul, who departed the role and the Board of Directors effective April 30, 2026.
- CCO Appointment: Michael McBreen was promoted from Executive Vice President to Chief Commercial Officer, effective May 1, 2026.
- Compensation Adjustments: New employment agreements were executed for both Dr. Essig and Mr. McBreen, establishing new base salaries, bonus targets, and equity grants.
Guidance, Outlook, and Management Commentary
The filing does not provide financial guidance, outlook, or general management commentary on business strategy. It focuses exclusively on the terms of the new executive appointments and the separation of the former CEO.
Risks, Contingencies, and Unusual Items
Executive Compensation and Severance Obligations:
- Dr. Essig (New CEO):
- Base Salary: $1,075,000 annually.
- Target Bonus: 125% of base salary.
- Initial Equity: $4,000,000 in RSUs and $4,000,000 in stock options (vesting over 3 years).
- Severance: Up to 2.0x salary + bonus for termination without cause; up to 2.99x for termination following a change in control.
- Ms. Poul (Former CEO):
- Separation Payment: Lump sum of $566,526 (cash-out of unvested RSUs and pro-rated 2026 bonus).
- Legal Fees: Reimbursement up to $25,000.
- Standard severance terms apply per her prior employment agreement for "Termination without Cause."
- Mr. McBreen (New CCO):
- Base Salary: $660,000 annually.
- Target Bonus: 90% of base salary.
- Initial Equity: $1,000,000 aggregate value (50% RSUs, 50% options).
- Future Equity: Target grant of $2,000,000 for the 2027 cycle.
Key Facts for Investor Verification
- Verify the impact of the leadership transition on the company's strategic direction, as Dr. Essig returns to the CEO role after serving as Chairman since 2012.
- Review the total cost of the separation package for Ms. Poul and the new compensation commitments for Dr. Essig and Mr. McBreen in the context of the company's cash flow.
- Confirm the vesting schedules for the new equity awards, particularly the accelerated vesting provisions triggered by change in control or retirement.
- Check the Definitive Proxy Statement (Schedule 14A) filed on April 6, 2026, for full details on Ms. Poul's post-employment benefits referenced in this filing.